louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01694927: Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients
Official title: Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Spinal Cord Injury
Keywords: Mesenchymal stem cell
Spinal cord injury
Lead sponsor: Clinica las Condes, Chile
Sponsor class: OTHER
First posted: 2012-09-27
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the use of autologous expanded mesenchymal stem cells intralesional transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.


Eligibility criteria: Inclusion Criteria:

* American Spinal Injury Association Impairment (ASIA) Scale A, B and C
* Cervical (under C4), thoracic o lumbar spine lesion
* Complete or Incomplete SCI
* Platelet count over 100.000/ul

Exclusion Criteria:

* Acute SCI (less than 3 months)
* Active infectious diseases
* Pregnancy
* Neurodegenerative diseases
* Primary hematologic diseases
* Coagulopathies
* Hepatic dysfunction
* Pregnancy

Primary outcomes:
measure: Safety of Autologous Expanded Mesenchymal Stem Cells transplantation in SCI patients
timeFrame: 3 months
Secondary outcomes:
measure: Functional improvement in muscle strength
timeFrame: 1 year
measure: Functional Improvement in sphincters control
timeFrame: 1 year
measure: Functional improvement in spasticity control
timeFrame: 1 year
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Clínica Las Condes
state: RM
Study officials:
affiliation: Clínica Las Condes, Santiago
name: Andrés Chahín, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Clínica Las Condes, Santiago
name: Rodrigo M Mardones, MD
role: STUDY_DIRECTOR
affiliation: Clínica Las Condes, Santiago
name: Catalina Larrain, MD
role: STUDY_CHAIR
References:
citation: Pal R, Venkataramana NK, Bansal A, Balaraju S, Jan M, Chandra R, Dixit A, Rauthan A, Murgod U, Totey S. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009;11(7):897-911. doi: 10.3109/14653240903253857.
citation: Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011 Aug;20(8):1297-308. doi: 10.1089/scd.2010.0466. Epub 2011 Mar 17.
citation: Moviglia GA, Fernandez Vina R, Brizuela JA, Saslavsky J, Vrsalovic F, Varela G, Bastos F, Farina P, Etchegaray G, Barbieri M, Martinez G, Picasso F, Schmidt Y, Brizuela P, Gaeta CA, Costanzo H, Moviglia Brandolino MT, Merino S, Pes ME, Veloso MJ, Rugilo C, Tamer I, Shuster GS. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy. 2006;8(3):202-9. doi: 10.1080/14653240600736048.
Clinical trial NCT04857827: A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Official title: A Randomized Active-controlled Study to Evaluate Safety and Tolerability of QLS-101 Versus Timolol Preservative Free (PF) Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Normal Tension Glaucoma (NTG)
Keywords: low tension glaucoma (LTG)
glaucoma
Lead sponsor: Qlaris Bio, Inc.
Sponsor class: INDUSTRY
First posted: 2021-04-23
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma


Eligibility criteria: Inclusion Criteria:

1. Visual acuity +1.0 logMAR or better
2. Willing to give informed consent
3. Ability to washout from current intraocular pressure lowering medications -

Exclusion Criteria:

1. All secondary glaucomas
2. Previous glaucoma intraocular or laser surgery (selective laser trabeculoplasty permitted when done 18 months or longer from Screening)
3. Refractive surgery
4. Ocular infection or inflammation

Primary outcomes:
measure: Ocular safety
timeFrame: 86 days
Secondary outcomes:
measure: Ocular hypotensive efficacy
timeFrame: 14 days
Other outcomes:
Locations:
city: Sioux Falls
country: United States
facility: Vance Thompson Vision
state: South Dakota
Study officials:
affiliation: Qlaris Bio, Inc.
name: B. Wirostko, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01237327: Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Official title: Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Metastatic Breast Cancer
Keywords: Metastatic Breast Cancer
Advanced
Postmenopausal
Exemestane vs Megestrol
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-11-09
Enrollment: 84
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or anti-estrogens plus chemotherapy and who had participated on an original study of exemestane vs megestrol : study 971-ONC-0028-080.


Eligibility criteria: Inclusion Criteria:

* Previous participation in study 971-ONC-0028-080.

Exclusion Criteria:

* Subjects who had not previously participated in study 971-ONC-0028-080.

Primary outcomes:
measure: Overall Survival
timeFrame: Every 12 weeks up to 6 years
Secondary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: Every 12 weeks up to 6 years
measure: Duration of Response (DR)
timeFrame: Every 12 weeks up to 6 years
measure: Time to Tumor Progression (TTP)
timeFrame: Every 12 weeks up to 6 years
measure: Time to Treatment Failure (TTF)
timeFrame: Every 12 weeks up to 6 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
city: Beijing
country: China
facility: PLA 307 Hospital
city: Nanjing
country: China
facility: Ba Yi Hospital, Cancer Center of CPLA
city: Nanjing
country: China
facility: Jiangsu Cancer Hospital
city: Shanghai
country: China
facility: Cancer Hospital
city: Tianjin
country: China
facility: The 2nd Central Hospital of Tianjin
city: Xi'an
country: China
facility: The 1st Affiliated Hospital, Xi'an Jiao Tong University
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00838227: Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
Official title: Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Schizophrenia
Keywords: Schizophrenia
Cognition
Obesity
Sedation
Lead sponsor: Manhattan Psychiatric Center
Sponsor class: OTHER
First posted: 2009-02-06
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent, will lead to improved cognition, increased wakefulness, and decreased weight in patients with schizophrenia who are on stable antipsychotic regimens

Detailed description: This study was withdrawn due to no source of funding to implement the study. No participants were enrolled for this study.

Eligibility criteria: Inclusion Criteria:

* Diagnostic and Statistical Manual-IV diagnosis of schizophrenia (all subtypes), illness duration greater than three years
* Auditory and visual acuity adequate to complete cognitive tests
* Stable dose of antipsychotics for at least 2 weeks prior to entry
* Good physical health determined by complete physical examination, laboratory tests, and EKG
* Capacity and willingness to give written informed consent.

Exclusion Criteria:

* Inability to read or speak English
* Documented disease of the central nervous system
* History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g. mental retardation)
* Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal, pulmonary or hematologic conditions;
* HIV positive
* Patients on antidepressants, including monoamine oxidase inhibitors
* Uncontrolled hypertension
* Pregnancy
* Patients with a current diagnosis of substance dependence
* Significant history of violence
* History of an eating disorder
* Ready for discharge within the following 8 weeks.

Primary outcomes:
measure: Cognitive changes as measured by the NIH MATRICS - Consensus Cognitive Battery (MCCB)
timeFrame: 8 weeks
Secondary outcomes:
measure: Sedation and weight changes
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Manhattan Psychiatric Center
name: Jean-Pierre Lindenmayer, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009 Jan;70(1):104-12. doi: 10.4088/jcp.07r03982. Epub 2008 Nov 18.
Clinical trial NCT03175627: Clinical Performance of Posterior Composite Tooth Fillings in Adults
Official title: Clinical Investigation Of A Bulk Fill Composite In Class II Restorations In Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Caries
Dental Restoration Failure
Keywords: Dental caries
Proximal surfaces
Posterior teeth
Carious lesions
Tooth diseases
Dental restorations
Composite resin
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans
Sponsor class: OTHER
Collaborators: name: 3M
First posted: 2017-06-05
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: In a split-mouth design, each participant will receive 2 matched restorations, one of each material.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether a new tooth-colored composite material is effective for load-bearing dental fillings.

Detailed description: In this post-market prospective randomized controlled clinical trial, posterior class II restorations will be evaluated for their clinical performance. The study will investigate the survival and efficacy of a bulk-filled composite resin restorative material for a period of 2 years. The bulk fill composite will be used according to indication and applied in approximal two- or three-surface restorations in permanent teeth.

Eligibility criteria: Inclusion Criteria:

* be older than 18 years of age
* have 2 back teeth with similar size tooth decay or failed fillings, that are in need of new moderate-size fillings
* both study teeth must be vital (tested with cold)
* both study fillings must be visible on the cheek-side of the tooth.

Exclusion Criteria:

* do not meet all inclusion criteria
* are under active orthodontic treatment
* have severe medical complications
* have dry mouth
* have chronic gum disease or poor oral hygiene
* are unavailable for long term recall (minimum of 2 years required)
* cannot tolerate the rubber dam
* have an unstable tooth contacts
* have severe bruxing or clenching, or are in need of jaw joint therapy
* are pregnant or breastfeeding.

Primary outcomes:
measure: Number of participants with restoration failure of either material
timeFrame: 2 years
Secondary outcomes:
measure: Clinical performance score for each restoration
timeFrame: 2 years
measure: Confirmation of material safety
timeFrame: 2 years
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: Lousiana State University Health Science Center, School of DentistrySchool of Dentistry
state: Louisiana
Study officials:
affiliation: LSUHSC School of Dentistry
name: Mathilde C Peters, DMD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06850727: A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
Official title: A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Ulcerative Colitis (UC)
UC - Ulcerative Colitis
Keywords: Ulcertative colitis
Inflammatory Bowel Diseases
Lead sponsor: Odyssey Therapeutics
Sponsor class: INDUSTRY
First posted: 2025-02-27
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.


Eligibility criteria: Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has a confirmed diagnosis of ulcerative colitis (UC)
* Has moderate to severely active UC as defined by the 3-component Modified Mayo clinic score
* Has an inadequate response, loss of response, or intolerance/medical contraindication to at least one of the following therapies: oral aminosalicylates, corticosteroids, immunosuppressants, anti-tumor necrosis factor biologic, anti-interleukin 12/23 biologic, Janus kinase inhibitors, or sphingosine-1-phosphate (S1P) modulators

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has diagnosis of Crohn's disease or indeterminate colitis
* Has had extensive colonic resection
* Has colostomy or ileostomy
* Has uncontrolled primary sclerosing cholangitis

Primary outcomes:
measure: Change in 3-component modified Mayo Clinic Score (MMCS) from baseline to after treatment with OD-07656
timeFrame: Baseline and 12 weeks
measure: Incidence of treatment-emergent adverse events (TEAEs) and treatment discontinuations due to TEAEs with OD-07656 treatment
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Proportion of participants who achieve clinical remission
timeFrame: Baseline and 12 weeks
measure: Proportion of participants who achieve clinical remission with vedolizumab treatment, following OD-07656 treatment
timeFrame: Baseline and 50 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Odyssey Therapeutics
name: Chief Medical Officer
role: STUDY_DIRECTOR
References:
Clinical trial NCT02576327: A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Official title: A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Vomiting
Keywords: Lymphoma
Aprepitant
Chemotherapy-induced nausea and vomiting (CINV)
Autologous Hematopoietic Stem Cell Transplantation
Hematological Malignancies
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2015-10-15
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Detailed description: Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of hematological malignancies. Although aprepitant has been shown to control CINV in highly emetogenic therapies for solid tumors, the antiemetic effect of aprepitant in hematological chemotherapies is still not clear. In this multi-central perspective randomized controlled study, the investigators are trying to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Eligibility criteria: Inclusion Criteria:

* Men and women \>/= 18 years, \<65 years
* Patients with lymphoma receiving autologous hematopoietic stem cell transplantation for the first time
* ECOG 0-2
* TBIL,AST and ALT \< 2.5-fold upper normal range
* Female and male subjects of childbearing potential must agree to use a medically accepted method of adequate contraception.
* Signed informed consent

Exclusion Criteria:

* Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma
* Women who are pregnant or breast feeding.
* Serious or uncontroled infection
* Serious complications
* Severe renal or hepatic disease
* Severe mental or nervous system diseases

Primary outcomes:
measure: Overall complete response (no emesis and no rescue therapy)
timeFrame: During and post chemotherapy (0-120 h)
Secondary outcomes:
measure: Time to initial neutrophil engraftment
timeFrame: 30 days post-transplantation
measure: Time to initial platelet recovery
timeFrame: 30 days post-transplantation
measure: Quality of Life
timeFrame: During and post chemotherapy (0-120 h)
measure: Safety and Tolerability assessed by possible side effects, and all AE will be reported during 30 days after the chemotherapy.
timeFrame: 30 days
Other outcomes:
Locations:
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Jun Zhu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04258527: Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
Official title: A Phase 1, Open-Label, Pharmacokinetic(PK), Pharmacodynamics(PD) and Safety Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2020-02-06
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase 1 study to investigate the characteristics of PK, PD and safety in subjects with advanced malignancies with FGF/FGFR alterations.


Eligibility criteria: Inclusion Criteria:

1. Men and women, aged 18 or older.
2. Histologically or cytologically confirmed malignancy which was considered to be surgically unresectable advanced, relapse or metastatic .
3. Radiographically measurable disease per RECIST v 1.1
4. Documentation of FGF/FGFR alteration..
5. Documented disease progression after standard therapy ,or no standard therapy available.
6. ECOG performance status of 0\~1.
7. Life expectancy ≥12 weeks

Exclusion Criteria:

1. Prior receipt of a selective FGFR inhibitor.
2. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).
3. Currently evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.
4. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed

Primary outcomes:
measure: Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of Pemigatinib as monotherapy
timeFrame: Day 1 to Day 16
measure: Time to maximum plasma concentration (Tmax) of Pemigatinib as monotherapy
timeFrame: Day 1 to Day 16
measure: Area under the single-dose plasma concentration-time curve (AUC0-t) of Pemigatinib as monotherapy
timeFrame: Day 1 to Day 16
Secondary outcomes:
measure: Safety of pemigatinib as monotherapy as assessed by the frequency, duration, and severity of adverse events
timeFrame: From screening through 30-35 days after end of treatment, up to 6 months
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Cancer Hospital of Tianjin Medical University
Study officials:
References:
Clinical trial NCT03490227: Measurement of Body Fat in Infants
Official title: Measurement of Body Fat in Infants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brown Adipose Tissue
Body Composition
Keywords: neonates
brown adipose tissue
body composition
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2018-04-06
Enrollment: 10
Sex: ALL
Minimum age (years): 14
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Up to 10 healthy, full term infants aged 14 to 28 days old at enrollment with no contraindications to MRI will be recruited to Pennington Biomedical Research Center to participate in this study which includes two study visits to be completed within 1-10 days apart.

Brief summary: Up to 10 infants will complete the study aimed to establish a technique for measuring whole body adiposity and brown adipose tissue in infant subjects using dual energy x-ray absorptiometry and magnetic resonance imaging, respectively.


Eligibility criteria: Inclusion Criteria:

* healthy, full-term infant
* aged 14-28 days at Visit 1

Exclusion Criteria:

* born preterm (\<37 weeks gestation)
* implanted metal or electronic objects that render MRI unsafe
* unable to complete 2 clinic visits 1-10 days apart at Pennington Biomedical Research Center

Primary outcomes:
measure: Whole Body Fat Mass
timeFrame: 1 day
measure: Average Brown Adipose Tissue Volume at First Visit
timeFrame: 1 day
measure: Average Brown Adipose Tissue Volume at Second Visit
timeFrame: 1 day
Secondary outcomes:
measure: Average Fat Signal Fraction of Brown Adipose Tissue at First Visit
timeFrame: 1 day
measure: Average Fat Signal Fraction of Brown Adipose Tissue at Second Visit
timeFrame: 1 day
measure: Reliability of Average Brown Adipose Tissue Volume Measurement Between the First and Second Visit
timeFrame: 2 days within 10 days apart
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
affiliation: Pennington Biomedical Research Center
name: Leanne M Redman, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: